- Home
- CGAU vs TVTX Comparison
CGAU vs TVTX Comparison
Compare CGAU & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGAU | TVTX |
|---|---|---|
| Founded | 2002 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CGAU | TVTX |
|---|---|---|
| Price | $19.83 | $30.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 15 |
| Target Price | $16.00 | ★ $37.43 |
| AVG Volume (30 Days) | 2.4M | ★ 2.7M |
| Earning Date | 02-19-2026 | 02-19-2026 |
| Dividend Yield | ★ 1.05% | N/A |
| EPS Growth | ★ 236.39 | N/A |
| EPS | ★ 1.60 | N/A |
| Revenue | ★ $1,285,392,000.00 | $435,826,000.00 |
| Revenue This Year | $14.70 | $121.25 |
| Revenue Next Year | $12.63 | $36.79 |
| P/E Ratio | $11.86 | ★ N/A |
| Revenue Growth | 2.66 | ★ 114.22 |
| 52 Week Low | $5.41 | $12.91 |
| 52 Week High | $20.40 | $42.13 |
Technical Indicators
Market Signals| Indicator | CGAU | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 65.74 | 44.07 |
| Support Level | $16.43 | $28.90 |
| Resistance Level | $17.98 | $30.65 |
| Average True Range (ATR) | 0.89 | 1.56 |
| MACD | 0.00 | 0.11 |
| Stochastic Oscillator | 87.03 | 31.64 |
Price Performance
Historical ComparisonAbout CGAU Centerra Gold Inc.
Centerra Gold Inc a gold mining and exploration company engaged in the operation, exploration, development, and acquisition of gold properties in Asia, North America, and other markets world-wide. The company reportable operating segments are Oksut; Mount; and Milligan Molybdenum. It derives maximum revenue from Oksut segment. Geographically, it operates in Turkey, United States, Canada and Other.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.